

# Global Peptide Cancer Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2026

<https://marketpublishers.com/r/GC5776887015EN.html>

Date: March 2021

Pages: 480

Price: US\$ 2,900.00 (Single User License)

ID: GC5776887015EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' Report highlights:

Global cancer Peptide Market Opportunity: > US\$ 20 Billion By 2026

Price, Dosage, Sales Insight On 22 Marketed Cancer Peptides

Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation

Comprehensive Clinical Insight On More Than 150 Cancer Peptides In Clinical Trials

Comprehensive Clinical Insight On More Than 20 Cancer Peptides Available In Market

Application of Peptides Therapeutics & Detection Methodology by Cancer

From past few years, there have been tremendous efforts for the development of novel cancer therapies which can enhance the targetability and specificity towards the cancer cells. The extensive research and development in this sector has enabled the researchers to utilize the therapeutic potential of small peptides in the management of cancer. The introduction of therapeutic peptides in the cancer therapeutic market has

greatly transformed the paradigm of cancer treatment.

The peptide therapeutics market is currently thriving due to their various advantages over other available cancer therapies. The lower toxicity of peptides can be credited to both their low instance of interaction with other molecules not of interest and also their ease of metabolism into their component amino acid residues. Furthermore their ease of manufacturing has attracted several pharmaceutical companies. In addition to this, their remarkable property to cross the blood brain barrier has attracted the researchers for the development of potential peptides targeting the receptors of various cancers.

Currently, there are several peptide based drug which are available in the market and have shown positive results in the management of wide range of cancers. The increased interest of the scientists can also be justified by the rapid approval of first peptide based cancer vaccine for treatment of prostate cancer. Moreover, slews of new peptides with positive preclinical studies have entered the clinical trials and are expected to enter the market in next few years. It is expected that the drugs will show great clinical response in comparison to other available cancer therapies.

The global peptide cancer therapeutic market is going to flourish in next few years due to several favourable parameters including their high specificity, rising investments in drug discover and the increase prevalence of cancer incidences. Furthermore, the increase in collaborations and partnerships among the pharmaceutical companies for the development of novel drugs in the management of cancer is going to boost the market. Despite this, there are several challenges such as their high manufacturing cost, limited oral bioavailability and low resistance to cleavage by serum proteases which restrain their growth in market.

In terms of revenue, North America is currently holding the top position and is expected to dominate the global peptide cancer market. This is mainly attributed to the region's potency in healthcare and a strong presence of various peptide based cancer therapeutic drug manufacturers is supporting the growth of the market in North America. Moreover, the presence of top key players such as Novartis, AstraZeneca, Teva Pharmaceuticals and Pfizer also favours the growth of this region.

On the other hand, Asia Pacific is expected to register considerable growth over the forecast period owing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. Cheaper cost of raw materials and patent expiration of blockbuster drugs boosting generic market is expected to provide

significant growth opportunities shortly. In coming years, the cancer therapeutics market will witness increasing adoption of novel peptide therapeutics and will contribute to a major share in the overall market.

'Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026' report provides insights into the potential application of peptide therapeutics and their mode of action in the management of different cancers. In addition to this, the report also provide data on the pricing, sales and dosage of the currently available peptide based therapeutics and the robust clinical pipeline which are expected to enter the market in next coming years. Moreover, the various key players which are indulging in research activities for the development of novel peptides is also added in the report.

## Contents

### **1. INTRODUCTION TO PEPTIDE THERAPEUTICS**

- 1.1 Overview of Peptide Therapeutics
- 1.2 Historical Perspective of Peptide Therapeutics
- 1.3 Classification Of Anti Cancer Peptides

### **2. DESIGNING & FUNCTIONING OF PEPTIDE DRUGS**

- 2.1 Rational Design Of Peptide Therapeutics
- 2.2 Approaches for Plasma Half Life Extension
- 2.3 Emerging Peptide Areas & Technologies
- 2.4 Peptide & Protein Interaction

### **3. SIGNIFICANCE OF PEPTIDES AS CANCER THERAPEUTICS**

### **4. TARGETS FOR THERAPEUTIC PEPTIDES**

- 4.1 Signal Transduction Pathways
- 4.2 Cell Cycle Regulation
- 4.3 Cell Death Pathways
- 4.4 Tumor Suppressor Protein
- 4.5 Transcription Factors

### **5. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS**

- 5.1 Peptide v/s Chemotherapy
- 5.2 Peptide v/s Monoclonal Antibody
- 5.3 Peptide v/s Gene Therapy
- 5.4 Peptide v/s Immunotherapy

### **6. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS**

- 6.1 Hormonal Peptides
- 6.2 Peptide as Radionuclide Drug Carrier
- 6.3 Peptide Vaccines
- 6.4 Peptides as Cytotoxic Drug Carrier
- 6.5 Anticancer Peptides

## 6.6 Other Anticancer Drugs Closely Related to Peptides

## **7. APPLICATION OF PEPTIDES THERAPEUTICS & DETECTION METHODOLOGY BY CANCER**

7.1 Colorectal Cancer

7.2 Lung Cancer

7.3 Pancreatic Cancer

7.4 Gastric Cancer

7.5 Breast Cancer

7.6 Prostate Cancer

## **8. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET OVERVIEW: CURRENT SCENARIO**

## **9. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW**

9.1 By Company

9.2 By Country

9.3 By Indication

9.4 By Patient Segment

9.5 By Phase

9.6 By Drug Formulation

## **10. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS INSIGHT**

10.1 Unknown

10.2 Research

10.3 Preclinical

10.4 Phase I

10.5 Phase I/II

10.6 Phase II

10.7 Phase II/III

10.8 Phase III

10.9 Preregistration

10.10 Registered

## **11. MARKETED CANCER PEPTIDES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION**

## **12. MARKETED CANCER PEPTIDES DRUGS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT**

- 12.1 Firmagon (Degarelix)
- 12.2 Eligard (Leuprolide)
- 12.3 Lupron (Leuprolide Acetate)
- 12.4 Histrelin Acetate (Supprelin LA/Vantas)
- 12.5 Gonax (Degarelix Acetate)
- 12.6 Trelstar (Treptorelin)
- 12.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
- 12.8 Plenaxis (Abarelix)
- 12.9 Velcade (bortizomib)
- 12.10 Ninlaro (Ixazomib)
- 12.11 Kyprolis (Carfilzomib)
- 12.12 Romidepsin (Istodax)
- 12.13 PegIntron (PegInterferon alpha-2b)
- 12.14 Sylatron (Peginterferon Alpha-2b)
- 12.15 Zoladex (Goserelin)
- 12.16 Cosmegen (Dactinomycin)
- 12.17 Somatuline Depot (lanreotide)
- 12.18 Suprefact (Buserelin)
- 12.19 Octreotide (Generic)
- 12.20 Sandostatin (Octeriotide Acetate)
- 12.21 Bynfezia Pen (Octeriotide)
- 12.22 Mepact (Mifamurtide)

## **13. ROLE OF PEPTIDES IN CANCER IMMUNOTHERAPY**

- 13.1 Overview
- 13.2 Peptide Vaccines for Immunotherapy

## **14. NEOANTIGEN VACCINE: AN EMERGING TUMOR IMMUNOTHERAPY**

- 14.1 Personalized Neoantigen Based Vaccine in Cancer
- 14.2 Clinical Progress & Future Prospects

## **15. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY**

15.1 Relevance of Venom Based Peptide Therapeutics

15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

## **16. ADVANCEMENTS IN PEPTIDE ONCOLOGY DRUGS**

## **17. GLOBAL PEPTIDE CANCER THERAPY MARKET DYNAMICS**

17.1 Favorable Market Parameters

17.2 Commercialization Challenges

## **18. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET FUTURE OUTLOOK**

## **19. COMPETITIVE LANDSCAPE**

19.1 Novartis

19.2 Amgen

19.3 Eli - Lilly

19.4 Merck

19.5 Pfizer

19.6 GlaxoSmithKline plc

19.7 Ipsen

19.8 Lonza Inc.

19.9 Roche

19.10 Takeda Pharmaceuticals

19.11 Teva Pharmaceuticals

19.12 Novo Nordisk A/S

19.13 PolyPeptide Group

19.14 AstraZeneca plc

19.15 Bachem Holding AG

19.16 Ferring Pharmaceuticals

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Classification of Anti-Cancer Peptides
- Figure 2-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
- Figure 3-1: Significance of Peptides as Cancer Therapeutics
- Figure 3-2: US - Per Unit Cost of Cancer Drug (US\$)
- Figure 4-1: Therapeutic Peptides Based on Their Biological Targets
- Figure 4-2: MAPK Signaling Pathways
- Figure 4-3: Cell Cycle in Eukaryotic
- Figure 4-4: Cell Death Pathways
- Figure 4-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
- Figure 5-1: Limitations of Monoclonal Antibody
- Figure 5-2: Monoclonal Antibodies & Peptide Therapeutics – Cost of Production per gram (US\$)
- Figure 5-3: Pre-Requisite for Gene Therapy
- Figure 5-4: Limitations of Gene Therapy
- Figure 5-5: Drawbacks of Immunotherapy
- Figure 6-1: Different Approaches of Peptide in Cancer Management
- Figure 6-2: Mode of Action – LHRH Agonist & LHRH Antagonist
- Figure 6-3: Effects of Somatostatin Analogs
- Figure 6-4: Peptide Receptor Radionuclide Therapy
- Figure 6-5: Mechanism of Peptide Vaccines
- Figure 6-6: Peptides in Clinical Trials
- Figure 7-1: Peptides & their Targets in CRC
- Figure 7-2: Peptides Undergoing Clinical Trials in CRC
- Figure 7-3: Peptides in Treatment of Lung Cancer
- Figure 7-4: Antigens Utilized as Molecular Targets
- Figure 7-5: Peptide Based Vaccines in Clinical Development
- Figure 7-6: Peptide Vaccine in Breast Cancer
- Figure 8-1: Global – Peptide Therapeutic Market Size (US\$ Billion), 2018 - 2026
- Figure 8-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US\$ Billion), 2019
- Figure 8-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2019
- Figure 8-4: Global – Peptide Oncology Drugs Market Size (US\$ Billion), 2018 - 2026
- Figure 8-5: Peptide Oncology Market – Regional Market Share (%), 2019



Figure 9-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026

Figure 9-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2021 till 2026

Figure 9-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2021 till 2026

Figure 9-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2021 till 2026

Figure 9-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2021 till 2026

Figure 9-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2021 till 2026

Figure 12-1: Firmagon – Years of Different Patent Issue

Figure 12-2: Firmagon – Expiration Year of Different Patents

Figure 12-3: Firmagon – Price for Single Supply of 80mg & 120mg Powder for Subcutaneous Injection (US\$), March'2021

Figure 12-4: Firmagon - Starting & Maintenance Dosage (mg)

Figure 12-5: Firmagon – Treatment Cost of Initial Cycle, Maintenance Cycle & Annual Treatment Cost (US\$), March'2021

Figure 12-6: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US\$), March'2021

Figure 12-7: Eligard – Recommended Dosage for Prostate Cancer on Monthly Basis (mg)

Figure 12-8: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US\$), March'2021

Figure 12-9: Eligard – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March'2021

Figure 12-10: Eligard – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US\$), March'2021

Figure 12-11: Lupron – Patent Issue & Expiration Year for Controlled Release Preparation

Figure 12-12: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation

Figure 12-13: Lupron – Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US\$), March'2021

Figure 12-14: Lupron – Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US\$), March'2021

Figure 12-15: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 12-16: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US\$), March'2021

Figure 12-17: Lupron – Recommended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), March'2021

Figure 12-18: Lupron – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 3.75mg Depot (US\$), January'201

Figure 12-19: Histrelin – FDA approval Year by Brand Name

Figure 12-20: Supprelin LA – FDA Approval Year by Brand Name

Figure 12-21: Histrelin – Price for Single 50mg Implant by Brand Name (US\$), March'2021

Figure 12-22: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US\$), March'2021

Figure 12-23: Gonax - Starting & Maintenance Dosage (mg)

Figure 12-24: Gonax – Treatment Cost of Initial Month, Maintenance Month & Annually (US\$), March'2021

Figure 12-25: Trelstar – Patent Issue & Expiration Year

Figure 12-26: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US\$), March'2021

Figure 12-27: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), March'2021

Figure 12-28: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US\$), March'2021

Figure 12-29: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US\$), March'2021

Figure 12-30: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 12-31: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US\$), March'2021

Figure 12-32: Global – Decapeptyl Annual Sales (Euro/US\$ Million), 2018-2020

Figure 12-33: Global – Decapeptyl Quarterly Sales (Euro/US\$ Million), 2019

Figure 12-34: Global – Decapeptyl Quarterly Sales (Euro/US\$ Million), 2020

Figure 12-35: Plenaxis – Number of Recommended Doses on Monthly Basis

Figure 12-36: Velcade – 1st & 2nd Patent Issue & Expiration Year

Figure 12-37: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US\$), March'2021

Figure 12-38: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US\$), March'2021

Figure 12-39: Global – Velcade Sales Value (JPY/US\$ Billion), 2017 - 2020

Figure 12-40: US – Velcade Sales Value (JPY/US\$ Billion), 2018 & 2019

- Figure 12-41: Global – Velcade Sales Value by Region (%), 2019
- Figure 12-42: Global – Velcade Quarterly Sales Value (JPY/US\$ Billion), Q1 & Q2, 2020
- Figure 12-43: Ninlaro – Patent Issue & Expiration Year
- Figure 12-44: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US\$), March'2021
- Figure 12-45: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), March'2021
- Figure 12-46: Ninlaro – Cost of 1 Treatment Cycle & Annual Treatment Cost for Multiple Myeloma (US\$), March'2021
- Figure 12-47: Ninlaro – Annual Sales Value (JPY/US\$ Billion), 2018-2020
- Figure 12-48: Ninlaro – Annual Sales by Region (%), 2019
- Figure 12-49: Global – Ninlaro Quarterly Sales Value (JPY/US\$ Billion), Q1-Q3, 2020
- Figure 12-50: Kyprolis – Proteolix Inc's Patents Issue & Expiration Year
- Figure 12-51: Kyprolis – Cydex Pharmaceutical's Patent Issue & Expiration Year
- Figure 12-52: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
- Figure 12-53: Kyprolis – Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US\$), March'2021
- Figure 12-54: Kyprolis – Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m<sup>2</sup> Per Week)
- Figure 12-55: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m<sup>2</sup> Twice a Week)
- Figure 12-56: Kyprolis – Annual Sales Value (US\$ Million), 2018-2020
- Figure 12-57: Kyprolis – Annual Sales by Region (%), 2020
- Figure 12-58: Global - Kyprolis Quarterly Sales Value (US\$ Million), Q1 – Q4, 2020
- Figure 12-59: US - Kyprolis Quarterly Sales Value (US\$ Million), Q1-Q4, 2020
- Figure 12-60: Romidepsin – FDA Approval Year by Indication
- Figure 12-61: Romidepsin – Price for a Supply of 10mg Branded & Generic Intravenous Powder (US\$), March'2021
- Figure 12-62: Romidepsin Intravenous Solution – Price for 5.5ml Supply & Price per ml of 5mg/ml Solution (US\$), March'2021
- Figure 12-63: Istodax – Cost of Single Dose & Single Treatment cycle (US\$), March'2021
- Figure 12-64: PegIntron - Patent Expiration Year by Region
- Figure 12-65: PegIntron – Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US\$), March'2021
- Figure 12-66: PegIntron Monotherapy – Dose by Weight of Patient (mcg), March'2021
- Figure 12-67: PegIntron Monotherapy – Reduced Dose by Weight of Patient (mcg), March'2021

Figure 12-68: Pegintron Combination – Duration of Treatment by Genotype (Weeks), March'2021

Figure 12-69: Sylatron – Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US\$), March'2021

Figure 12-70: Sylatron – Initial & Maintenance Dose (mcg/Kg/Week), March'2021

Figure 12-71: Sylatron – Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), March'2021

Figure 12-72: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US\$), March'2021

Figure 12-73: Sylatron - Average Cost of Single Maintenance Dose, Annual Maintenance Cost & Full Maintenance Phase (US\$), January'2020

Figure 12-74: Zoladex – Patent Issue & Expiration Year

Figure 12-75: Zoladex - Cost of 3.6mg & 10.8mg Implant (US\$), March'2021

Figure 12-76: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (MG), March'2021

Figure 12-77: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US\$), March'2021

Figure 12-78: Global - Zoladex Annual Sales Value (US\$ Million), 2017 - 2020

Figure 12-79: Zoladex – Annual Sales by Region (US\$ Million), 2020

Figure 12-80: Zoladex – Annual Sales by Region (%), 2020

Figure 12-81: US - Zoladex Annual Sales Value (US\$ Million), 2017 - 2019

Figure 12-82: Europe - Zoladex Annual Sales Value (US\$ Million), 2017 - 2020

Figure 12-83: Zoladex – Quarterly Sales Value (US\$ Million), Q1 – Q4, 2020

Figure 12-84: Dactinomycin – Price for Generic & Branded 0.5mg Powder for Injection (US\$), March'2021

Figure 12-85: Cosmegen – Average Cost of Treatment for Wilm's Tumor (US\$), March'2021

Figure 12-86: Cosmegen – Average Cost of One Cycle & Full Treatment Cost For Rhabdomyosarcoma (US\$), March'2021

Figure 12-87: Cosmegen – Cost of One Cycle & Full Treatment Cost for Ewing's Tumor (US\$), March'2021

Figure 12-88: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US\$), March'2021

Figure 12-89: Cosmegen – Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US\$), March'2021

Figure 12-90: Cosmegen – Full Treatment Cost of Upper & lower Body Solid Tumor (US\$), March'2021

Figure 12-91: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US\$), March'2021

Figure 12-92: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatuline Depot Subcutaneous Solution (US\$), March'2021

Figure 12-93: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatuline Depot Subcutaneous Solution (US\$), March'2021

Figure 12-94: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US\$), March'2021

Figure 12-95: Global – Somatuline Annual Sales (Euro/US\$ Million), 2018-2020

Figure 12-96: Global – Somatuline Quarterly Sales (Euro/US\$ Million), 2019

Figure 12-97: Global – Somatuline Quarterly Sales (Euro/US\$ Million), 2020

Figure 12-98: Suprefact – Price of 6.3mg & 9.45mg Depot (US\$), March'2021

Figure 12-99: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US\$), March'2021

Figure 12-100: Suprefact Injection – Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day), March'2021

Figure 12-101: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), March'2021

Figure 12-102: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US\$), March'2021

Figure 12-103: Octreotide - Cost of 10ml Supplies of Various Dose Regimens (US\$), March'2021

Figure 12-104: Octreotide – Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), January'2021

Figure 12-105: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US\$), March'2021

Figure 12-106: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US\$), March'2021

Figure 12-107: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US\$), March'2021

Figure 12-108: Sandostatin LAR – Price for Various Supplies of Intramuscular Powder for Injection, March'2021

Figure 12-109: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), March'2021

Figure 12-110: Global - Sandostatin Annual Sales Value (US\$ Million), 2018-2020

Figure 12-111: Global – Sandostatin Quarter Sales Value (US\$ Million), 2020

Figure 12-112: Bynfezia Pen – Patent Issue & Expiration Year

Figure 12-113: Bynfezia Pen – Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US\$), January'2021

Figure 12-114: Bynfezia Pen – Price for 5.6ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US\$), January'2021

Figure 12-115: Bynfezia Pen – Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)

Figure 12-116: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment

Figure 12-117: Germany – Cost of Single Dose & Full Treatment (EUR/US\$), March'2021

Figure 13-1: Role of Peptides in Cancer Immunotherapy

Figure 14-1: Benefits of Neoantigens

Figure 14-2: Steps of Producing Neoantigen Vaccine

Figure 14-3: Neoantigen Vaccine - Mode of Action

Figure 14-4: Neoantigen Vaccine in Clinical Development

Figure 15-1: Advantages of Venom Peptides

Figure 15-2: Other Venom Peptides in Cancer Therapy

Figure 15-3: Venom Peptides in Clinical Pipeline

Figure 16-1: Mechanism of Action of the BC71 Peptide by Targeting Cell-Surface GRP78 in Cancer

Figure 17-1: Favorable Market Parameters

Figure 17-2: Commercialization Challenges

Figure 18-1: Global – Somatostatin Analogues Market Size (US\$ Million), 2020 - 2024

Figure 18-2: Clinical Timeline of Therapeutic Peptides

## I would like to order

Product name: Global Peptide Cancer Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/GC5776887015EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC5776887015EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

